# VYNDAQEL
> **NDA211996** · New Drug Application · Sponsor: FOLDRX PHARMS · Approved 2019-05-03
## Drug
- **FDA Application Number:** NDA211996
- **Application type:** New Drug Application
- **Brand name:** VYNDAQEL
- **Generic name:** TAFAMIDIS MEGLUMINE
- **Active ingredients:** TAFAMIDIS MEGLUMINE
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Discontinued
- **Sponsor:** FOLDRX PHARMS
- **Manufacturer:** Pfizer Laboratories Div Pfizer Inc
- **First approval:** 2019-05-03
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211996)
---
*AI Analytics · CC0 1.0*